President Obama’s recent reversal of Bush’s policy on embryonic stem cell research reignited the debate over the ethical limits of science. However, as the Wall Street Journal reports, an innovative new technique could potentially reproduce the benefits of embryonic stem cells without the attendant controversy.
Big news at ORTHOCON, DeviceSpace reports. The New Jersey-based company, which develops devices that deliver therapeutics to bone, recently announced the appointment of a new CEO and the closing of $25 million in Series B funding.
Many patients are left humiliated and depressed because of the daily disruptions caused by urinary or fecal incontinence. Vermont company AugmentRX is developing incontinence solutions for the 200 million-plus people worldwide who suffer from this debilitating condition.
A new analysis of AstraZeneca’s cholesterol-lowering statin Crestor shows that the drug sharply reduces the risk of venous thromboembolism (VTE), a potentially fatal disorder in which blood clots can form in the legs and travel to the lungs.
Only 9 percent of U.S. hospitals use electronic medical records, according to a new survey. It’s a far cry from the comprehensive, high-tech environment supported by the Obama and Bush administrations.
Solid tumors represent 85 percent of all cancers, creating a huge clinical need for localized, site-specific cancer treatment. Inovio Medical Corporation of San Diego is developing DNA-based vaccines that harness the body’s immune system to prevent and treat chronic diseases such as cancer and HIV.
Identifying a cardiac arrhythmia is an important first step in diagnosing a potentially life-threatening heart condition. Texas-based eCardio Diagnostics, a leading provider of digital holter monitors, seeks to improve the speed and accuracy of this process.
Tuberculosis, or TB, is one of the world’s most widespread lethal diseases, killing someone every 20 seconds. An estimated one-third of the world’s population is infected with tuberculosis. Current medications for TB must be taken for six months, but many patients stop before they’ve completed the full course, which has caused drug-resistant strains of TB to develop in recent years. However, two new studies are showing promise in treating this highly infectious disease.
According to Science Daily, the Albert Einstein College of Medicine at Yeshiva University found that a combination of two FDA-approved antibiotics showed potential for treating drug-resistant TB. One of the drugs, clavulanate, inhibits a bacterial enzyme that normally protects TB bacteria from the other antibiotic (meropenem). Clinical trials of the combined treatment are scheduled to take place later this year in South Africa and South Korea.
One of the most important steps in spinal implant surgery is removing all nucleus material from the lumbar disc before inserting the implant. If any […]
Copyright © 2024 | WordPress Theme by MH Themes